Bio-Techne Stock Rating (NASDAQ: TECH) Improved by Stephens
Bio-Techne (NASDAQ: TECH) was reclassified by Stephens equity research analysts from a ‘on par’ rating to an ‘overweight’ rating in a research report released on Monday, Fly reports.
A number of other analysts have also published reports on TECH. Stifel Nicolaus upgraded Bio-Techne’s shares from a “hold” rating to a “buy” rating and set a target price of $ 435.00 on the stock in a research report on Monday March 1 . Citigroup raised its price target on Bio-Techne shares from $ 310.00 to $ 400.00 and rated the company “neutral” in a report on Wednesday, February 3. Benchmark raised its price target on Bio-Techne shares from $ 320.00 to $ 410.00 and gave the company a “buy” rating in a report on Monday, January 25. KeyCorp assumed coverage of Bio-Techne’s shares in a report on Monday, November 9. They issued a “sector weight” rating and a target price of $ 340.00 on the stock. Finally, Craig Hallum raised his price target on Bio-Techne shares from $ 352.00 to $ 440.00 and gave the company a “buy” rating in a report on Wednesday, February 3. One research analyst rated the stock with a sell rating, three assigned a sustaining rating, and seven assigned a buy rating to the stock. The company currently has a “Buy” consensus rating and an average target price of $ 347.27.
Actions of NASDAQ TECH open for $ 356.21 on Mondays. Bio-Techne has a one-year minimum of $ 155.17 and a one-year maximum of $ 414.99. The company’s 50-day average mobile price is $ 367.23, and its 200-day average mobile price is $ 302.79. The company has a market cap of $ 13.82 billion, a P / E ratio of 56.99, a price / earnings-growth ratio of 7.23 and a beta of 1.13. The company has a debt ratio of 0.22, a rapid ratio of 4.13 and a current ratio of 5.14.
Bio-Techne (NASDAQ: TECH) last reported its financial results on Monday, February 1. The biotech company reported earnings per share (EPS) of $ 1.62 for the quarter, beating the Zacks consensus estimate of $ 1.37 per $ 0.25. Bio-Techne had a net margin of 32.69% and a return on equity of 12.20%. The company posted revenue of $ 224.30 million for the quarter, compared to analysts’ estimates of $ 206.50 million. In the same quarter of last year, the company made earnings per share of $ 1.08. Bio-Techne’s revenue increased 21.3% compared to the same quarter last year. As a group, equity analysts predict that Bio-Techne will post 5.08 EPS for the current year.
Separately, insider Kim Kelderman sold 823 Bio-Techne shares in a trade dated Friday, February 5. The shares were sold for an average price of $ 388.45, for a total value of $ 319,694.35. Following the closing of the transaction, the insider now directly owns 845 shares of the company, valued at approximately $ 328,240.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, available at this link. In addition, CFO James Hippel sold 10,000 shares of Bio-Techne in a transaction dated Monday, January 11. The shares were sold for an average price of $ 333.63, for a total transaction of $ 3,336,300.00. Following the closing of the transaction, the CFO now directly owns 19,137 shares of the company, valued at $ 6,384,677.31. Disclosure of this sale can be found here. Insiders have sold a total of 30,823 shares of the company valued at $ 10,535,994 in the past 90 days. Company insiders own 3.80% of the company’s shares.
A number of institutional investors have recently bought and sold TECH shares. William Blair Investment Management LLC acquired a new position in Bio-Techne during the 4th quarter valued at approximately $ 232,063,000. Norges Bank acquired a new position in Bio-Techne during the 4th quarter valued at approximately $ 109,774,000. Ownership Capital BV increased its stake in Bio-Techne by 28.2% in the 4th quarter. Ownership Capital BV now owns 972,263 shares of the biotech company valued at $ 88,700,000 after purchasing an additional 213,896 shares during the period. Select Equity Group LP acquired a new position in Bio-Techne during the 4th quarter valued at approximately $ 67,810,000. Finally, Wells Fargo & Company MN increased its stake in Bio-Techne by 313.6% in the 3rd quarter. Wells Fargo & Company MN now owns 203,342 shares of the biotech company valued at $ 50,374,000 after purchasing an additional 154,182 shares during the period. 93.75% of the shares are held by hedge funds and other institutional investors.
Bio-Techne Corporation, along with its subsidiaries, develops, manufactures and sells life science reagents, instruments and services for the research and clinical diagnostic markets around the world. The company operates in two segments, protein sciences and diagnostics and genomics. The Protein Sciences segment offers proteins and reagent solutions, including cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and activation technologies. T cells.
Learn more: Stochastic Momentum Index (SMI)
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]